II. Preparations
- Bacitracin
- Mupirocin (Bactroban) 2% ointment
- Impetigo: Applied three times daily to affected area for 7-10 days
- May be used in age 2 months and older
- Available as 22 g tube (ointment is less expensive than creams)
- Emerging Streptococcal resistance in 2014
-
Retapamulin (Altabax) 1% ointment
- Impetigo: Apply twice daily to affected area for 5 days
- May be used in age 9 months and older
- Treatment area must be <100 cm2 (or <2% total BSA in children)
- Fusidic Acid 2% cream (Not available in United States)
- Impetigo: Apply three times daily to affected area for 10-12 days
- Koning (2002) BMJ 324:203-6 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
| bacitracin (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| BACITRACIN 500 UNIT/GM OINTMNT | Generic OTC | $0.07 per gram |
| BACITRACIN 500 UNIT/GM OPHTHALMIC OINTMENT | Generic | $30.53 per gram |
| BACITRACIN ZN 500 UNIT/GM OINT | Generic OTC | $0.07 per gram |
| BACITRACIN-POLYMYXIN EYE OINT | Generic | $2.64 per gram |
| mupirocin (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| MUPIROCIN 2% CREAM | Generic | $2.75 per gram |
| MUPIROCIN 2% OINTMENT | Generic | $0.17 per gram |
Ontology: Bacitracin (C0004599)
| Definition (NCI) | A complex of cyclic polypeptide antibiotics, mainly bacitracin A, produced by spore-forming organisms belonging to the licheniformin group of the Bacillus subtilis with antibacterial activity. Bacitracin binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule that carries the building blocks of the peptidoglycan bacterial cell wall. The binding interferes with the enzymatic dephosphorylation of the C55-isoprenyl pyrophosphate and prevents peptidoglycan synthesis, thereby inhibiting bacterial cell growth. |
| Definition (MSH) | A complex of cyclic peptide antibiotics produced by the Tracy-I strain of Bacillus subtilis. The commercial preparation is a mixture of at least nine bacitracins with bacitracin A as the major constituent. It is used topically to treat open infections such as infected eczema and infected dermal ulcers. (From Goodman and Gilman, The Pharmacological Basis of Therapeutics, 8th ed, p1140) |
| Concepts | Antibiotic (T195) , Amino Acid, Peptide, or Protein (T116) |
| MSH | D001414 |
| SnomedCT | 255965000, 5220000, 370330005 |
| LNC | LP14906-9, MTHU002155 |
| English | bacitracin, bacitracin (medication), BACITRACIN, Bacitracin [Chemical/Ingredient], Bacitracin (substance), Bacitracin product (product), Bacitracin product, BAC, Bacitracin, Bacitracin, NOS, Bacitracin [dup] (substance) |
| Swedish | Bacitracin |
| Czech | bacitracin |
| Finnish | Basitrasiini |
| Russian | BATSITRATSIN, БАЦИТРАЦИН |
| Spanish | bacitracina (producto), producto con bacitracina (producto), producto con bacitracina, bacitracina (sustancia), bacitracina, Bacitracina |
| Polish | Bacytracyna |
| Japanese | バシトラシン, アイフィビス |
| French | Bacitracine |
| German | Bacitracin |
| Italian | Bacitracina |
| Portuguese | Bacitracina |
Ontology: Mupirocin (C0085259)
| Definition (NCI) | A natural crotonic acid derivative extracted from Pseudomonas fluorescens. Mupirocin inhibits bacterial protein synthesis by specific reversible binding to bacterial isoleucyl tRNA synthase. With excellent activity against gram-positive staphylococci and streptococci, it is primarily used for treatment of primary and secondary skin disorders, nasal infections, and wound healing. (NCI04) |
| Definition (MSH) | A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing. |
| Concepts | Lipid (T119) , Antibiotic (T195) |
| MSH | D016712 |
| SnomedCT | 387397004, 71453003 |
| LNC | LP17279-8, MTHU009172 |
| English | Acid, Pseudomonic, Mupirocin, Pseudomonic Acid, Pseudomonic Acid A, Nonanoic acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)methyl)-2H-pyran-2-yl)-2-butenyl)oxy)-, (2S-(2alpha(E),3beta,4beta,5alpha(2R*,3R*(1R*,2R*))))-, mupirocin, mupirocin (medication), MUPIROCIN, Mupirocin [Chemical/Ingredient], pseudomonic acid a, Pseudomonic acid, Pseudomonic acid A, Mupirocin (product), Mupirocin (substance) |
| Swedish | Mupirocin |
| Czech | mupirocin |
| Finnish | Mupirosiini |
| Russian | MUPIROTSIN, PSEVDOMONOVAIA KISLOTA, МУПИРОЦИН, ПСЕВДОМОНОВАЯ КИСЛОТА |
| Italian | Acido pseudomonico, Acido pseudomonico A, Mupirocina |
| Polish | Mupirocyna, Kwas pseudomonowy |
| Japanese | プソイドモニックアシド, ムピロシン |
| Spanish | Ácido Pseudomónico, mupirocina (producto), mupirocina (sustancia), mupirocina, ácido pseudomónico A, ácido pseudomónico, ácido seudomónico, Mupirocina, Ácido Seudomónico |
| French | Acide pseudomonique, Mupirocine |
| German | Mupirocin, Pseudomonassäure |
| Portuguese | Ácido Pseudomônico, Mupirocina |
Ontology: Bactroban (C0733863)
| Concepts | Lipid (T119) , Antibiotic (T195) |
| MSH | D016712 |
| English | bactroban, Bactroban |
